Güzelöz, ZelihaGörken, İlknur BilkayAydın, BarbarosSert, FatmaYalman, DenizParvizi, MurtazaAvcı, Gülhan GülerAltınok, PelinHalis, HaticeErgen, Şefika ArzuAkgün, ZüleyhaÖzkan, ElifGüney, YıldızKaraçetin, DidemKaydıhan, NuriDüzova, MürselAkın, MuratUysal, BoraErdoğan, MihribanEllidokuz, HülyaAksu, GamzeMetcalfe, Evrim2024-04-192024-04-192024Güzelöz, Z., Görken, İ. B., Aydın, B. Sert, F., Yalman, D., Parvizi, M. ... Metcalfe, E. (2024). Evaluation of treatment outcomes and tolerability in older patients with rectal cancer treated with radiotherapy accompanied by the G-8 geriatric score: TROD13–003 multicenter study. Journal of Geriatric Oncology, (15)3. http://dx.doi.org/10.1016/j.jgo.2024.1017391879-4068http://dx.doi.org/10.1016/j.jgo.2024.101739https://hdl.handle.net/20.500.12511/12418Introduction: The choice of treatment for rectal cancer often differs in older and younger patients, with the rate of radiotherapy use lower among older adults. In our daily practice, when evaluating a frail older patient with rectal cancer, we usually choose to give less treatment. This may be due to concern that the patient will not be able to tolerate radiotherapy. The Geriatric 8 score (G8GS) is a guide to evaluating treatment tolerability as it relates to frailty in older adults with cancer. The aim of this study was to evaluate treatment outcomes and tolerability in older patients with rectal cancer treated with radiotherapy (RT) accompanied by G8GS. Materials and Methods: Patients aged 65 and older with stage I-III rectal adenocarcinoma who were treated with RT and had a G8 evaluation were included in this multicenter retrospective study. Prognostic factors related to G8GS were calculated using Chi-square and logistic regression tests and survival rates were calculated by the Kaplan–Meier test using the SPSS v24.0 software. All p-values ?0.05 were considered statistically significant. Results: A total of 699 patients from 16 national institutions were evaluated. The median age was 72 years (range 65–96), and the median follow-up was 43 (range 1- 190) months. Four hundred and fifty patients (64%) were categorized as frail with G8GS ?14 points. Frail patients had higher ages (p = 0.001) and more comorbidities (p = 0.001). Ability to receive concomitant and/or adjuvant chemotherapy rates were significantly higher in fit patients (p = 0.002 and p = 0.001, respectively). No significant difference was observed in terms of grade 3-4 early and late toxicity for both groups. Cancer-related death was higher (p = 0.003), and 5- and 8-year survival rates were significantly lower (p = 0.001), in the frail group. Age and being frail were significantly associated with survival.eninfo:eu-repo/semantics/openAccessCapecitabineFluorouracilBiological MarkerAdjuvant ChemotherapyAdjuvant TherapyAge DistributionAgedArticleCancer MortalityCancer PatientCancer PrognosisCancer RadiotherapyCancer StagingCancer SurvivalChi Square TestClinical OutcomeCohort AnalysisComorbidityConformal RadiotherapyControlled StudyEvaluation ResearchFemaleFitnessFollow UpFrail ElderlyG 8 Geriatric ScoreGeriatric AssessmentHumanKaplan Meier MethodLocal Recurrence Free SurvivalLogistic Regression AnalysisMajor Clinical StudyMaleMetastasis Free SurvivalMulticenter Study (Topic)Overall SurvivalPatient CodingPatient SelectionProctitisPrognostic AssessmentRadiation ToxicityRectal AdenocarcinomaRectum CancerRetrospective StudyStatistical SignificanceSurvival RateTherapyTreatment OutcomeTreatment TolerabilityVery ElderlyVolumetric Modulated Arc TherapyAdultData Analysis SoftwareDrug TherapyFrailtyGeriatric AssessmentRadiotherapyRectal AdenocarcinomaRectum CancerSpecial Situation For PharmacovigilanceTherapy EffectArticle15310.1016/j.jgo.2024.1017392-s2.0-8518799793638492350Q2